Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: The emerging role of erlotinib

Journal of B.U.ON.

Volumn 12, Issue SUPPL. 1, 2007, Pages

  Dediu, Mircea ^a   Median, Dragos ^a   Alexandru, Aurelia ^a   Vremes, Georgeta ^a   Gal, Cristian ^a  

^a Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

Author keywords

Erlotinib; Non small cell lung cancer; Pancreatic cancer; Tyrosine kinase inhibitors

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GELDANAMYCIN; GEMCITABINE; IMATINIB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE OVEREXPRESSION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHARMACOGENETICS; PREDICTION; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC SCREENING; HUMANS; LUNG NEOPLASMS; MUTATION; PANCREATIC NEOPLASMS; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 36749039760     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombert M, Boyle P. Estimates of the cancer incidence and mortality in Europe 2006. Ann Oncol 2007; 18: 581-592.
2. Pfister D, Johnson D, Azzoli C et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 2004; 22: 330-353.
3. Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys 2004; 58: 991-1002.
4. Yarden Y, Sliwkowski MX Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
5. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002; 110: 669-672.
6. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: Mechanisms of activation and signaling. Exp Cell Res 2003; 284: 31-53.
7. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49-139.
8. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
9. Yamamoto T, Hihara H, Nishida T. Anew avian erythroblastosis virus, AEV-H, carries erbB gene responsible for the induction of both erythroblastosis and sarcomas. Cell 1983; 34: 225-232
10. Pao W, Miller V. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 2005; 23: 2556-2568.
11. Bunn PA, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29 (Suppl 14): 38-44.
12. Meert A-P, Martin B, Delmotte P et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002; 20: 975-981.
13. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006; 61: 140-145.
14. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD 1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-4302.
15. Moyer J, Barbacci E, Iwata K et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838-4848.
16. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
17. Kris M, Natale RB, Herbst R et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003; 290: 2149-2158.
18. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-3247.
19. Kris M, Sandler A, Cespon M et al. Cigarette smoking history predicts sensitivity to erlotinib (Tarceva): results of a phase II trial in patients with bronchioloalveolar cancer (BAC). Proc Am Soc Clin Oncol 2004; 22: 7062 (abstr).
20. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-4892.
21. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785-794.
22. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777-784.
23. Gatzemeier U, Pluzanska A, Szczesna A et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Onc 2004; 22: 7010 (abstr).
24. Herbst RS, Prager D, Hermann R et al. TRIBUTE - A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc, Clin One 2004; 22:7011 (abstr).
25. Gandara D, Gumerlock P. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: Case closed or is the jury still out? J Clin Oncol 2005; 23: 5856-5858.
26. Siegel-Lakhai W, Beijnen J, Schellens J. Current knowledge and future directions of the selective epidennal growth factor receptor inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®). Oncologist 2005; 10: 579-589.
27. Eberhard D, Johnson B, Amler L. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinin. J Clin Oncol; 2005; 23: 5900-5909.
28. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
29. Thatcher N, Chang A, Parikh P et al. Results of a phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced nonsmall-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens. Proc Am Assoc Cancer Res 2005; Late Breaking Session: LB-6.
30. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
31. Lacouture E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803-812.
32. Clark G, Zborowski D, Culbertson J et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol 2006; 1: 837-846.
33. Tsao M-S, SakuradaA, Cutz J-C et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2006; 353: 133-144.
34. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
35. Hirsch F, Varella-Garcia M, Bunn P. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-5042.
36. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118: 257-262.
37. Riely GJ, Pao W, Pham D et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12: 839-844.
38. Anido J, Matar P, Albanell J et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003; 9: 1274-1283.
39. Han SW, Kim TY, Hwang PG et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-2501.
40. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-celllular lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-2520.
41. Takano T, Ohe Y, Sakamoto H et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitimb sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 6829-6837.
42. Cortes-Funes H, Gomez C, Rosell R et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005; 16: 1081-1086.
43. Shepherd FA, Tsao MS. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006; 24: 1219-1221.
44. Inoue A, Suzuki T, Fukuhara T et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24: 3340-3346.
45. Paz-Ares L, Sanchez JM, Garcia-Velasco A et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2006; 24: 369s, 7020 (abstr).
46. Okamoto I, Kashii T, Urata Y et al. EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): results of West Japan Thoracic Oncology Group trial (WJTOG0403). Proc Am Soc Clin Oncol 2006; 24: 382s, 7073 (abstr).
47. Pao W, Wang T, Riely G et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitimb or erlotinib. PLoS Med 2005; 2: e 17.
48. Ahrendt SA, Decker PA, Alawi EA et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92: 1525-1530.
49. Tsao M, Zhu C, Sakurada A et al. An analysis of the prognostic and predictive importance of K ras mutation status in the National Cancer Institute of Canada Clinical trials Group BR 21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. J Clin Oncol 2006 24: 365s, 7005 (abstr).
50. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
51. Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Nad Acad Sci USA 2005; 102: 7665-7670.
52. Shimamura T, Lowell AM, Engelman JA, Shapiro G. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005; 65: 6401-6408.
53. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
54. Kosaka T, Yatabe Y, Endoh H et al. Analysis of EGFR gene mutation in patients with non-small-cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006; 12: 5764-5769.
55. Jackman DM, Yeap BY, Sequist IV et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12: 3909-3914.
56. Hirsch FR, Franklin WA, McCoy J et al. Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. Proc Am Soc Clin Oncol 2006; 24: 382s, 7072 (abstr).
57. Sohn TA, Yeo CJ, Cameron JL et al. Resected. adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.
58. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996; 46: 5-27.
59. Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
60. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 2002; 20: 3270-3275.
61. Di Costanzo F, Carlini P, Doni L et al. Gemcitabine with or without continuous inftision 5-FU in advanced pancreatic cancer: A randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 2005; 93: 185-189.
62. Riess H, Helm A, Niedergethmann I et al. A randomized, prospective, multicentre, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23 (Suppl): 1092(S 16; abstr 4009).
63. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer: A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol 2005; 23 (Suppl): 1092 (S 16; abstr 4010).
64. Cunningham D, Chan I, Stocken D et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 2005; 4: PS 11 (abstr).
65. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-3783.
66. Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-1645.
67. Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic carcinoma. J Clin Oncol 2006; 24: 3946-3952.
68. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516.
69. Poplin E, Levy D, Berlin J et al. Phase III trial of gemcitabine (30 mininfusion) versus gemcitabine (fixed-dose rate infusion (FDR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 2006; 24 (Suppl): 18S, 4004 (abstr).
70. Louvet C, Hincke A, Labianca I, Heinemann V. Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): Pooled analysis of two randomised trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study. J Clin Oncol 2006; 24 (Suppl): 18S, 4003 (abstr).
71. Xie de R, Liang H, Wang Y, Guo SS, Yang Q. Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone. Chin J Digest Dis 2006; 7: 49~54.
72. Tobita K, Kijima H, Dowaki S et al. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 2003; 11: 305-309.
73. Moore MJ, Goldstein D, Hamm J et al. Erlotinib improves survival when added to gemcitabine inpatients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin Oncol 2007; 25: 1960-1966.
74. Van Custe E, Verslype C. Lessons learned in the management of advanced pancreatic cancer. J Clin Oncol 2007; 25: 1949-1966.